Hyperlipidemia patients with long-term statin treatment are associated with a reduced risk of progression of benign prostatic enlargement

Hung Jen Shih, Pei Shan Tsai, Yu Ching Wen, Ming Chang Kao, Yen Chun Fan, Chun Jen Huang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To evaluate the impacts of statin treatment on the risk of benign prostatic enlargement (BPE) progression in hyperlipidemia patients. Methods: Newly diagnosed hyperlipidemia patients (n = 7961), identified from Taiwan’s National Health Insurance Research Database, were divided into four statin cohorts (statin use >365 days, n = 1604; statin use 181–365 days, n = 813; statin use 91–180 days, n = 739; and statin use 31–90 days, n = 713) and one control cohort (cohort that used no statins, n = 4092). Study endpoint was occurrence of BPE progression (BPE diagnosis plus receiving BPE-related medications or surgery). Relative risks of BPE progression in the statin cohorts compared to the control cohort were analyzed. Results: Multivariable Cox proportional hazards regression analyses demonstrated that BPE progression risk in the cohort used statins for >365 days was significantly lower than the control cohort (adjusted hazard ratio: 0.70, 95% confidence interval: 0.58 ∼ 0.85, p <.001). However, BPE progression risks of the other three statin cohorts did not significantly differ from the control cohort. Trend analysis revealed that the effects of statin treatment on decreasing BPE progression risk were significantly related to statin treatment duration (p =.001). Conclusions: Hyperlipidemia patients with long-term statin treatment (more than 365 days) are associated with a reduced risk of BPE progression.

Original languageEnglish
JournalAging Male
DOIs
Publication statusPublished - 2018

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipidemias
Therapeutics
National Health Programs

Keywords

  • benign prostate enlargement
  • hyperlipidemia
  • progression
  • prostate
  • Statin

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

@article{a28c02d8ad544d7b980ac9112352198c,
title = "Hyperlipidemia patients with long-term statin treatment are associated with a reduced risk of progression of benign prostatic enlargement",
abstract = "Objective: To evaluate the impacts of statin treatment on the risk of benign prostatic enlargement (BPE) progression in hyperlipidemia patients. Methods: Newly diagnosed hyperlipidemia patients (n = 7961), identified from Taiwan’s National Health Insurance Research Database, were divided into four statin cohorts (statin use >365 days, n = 1604; statin use 181–365 days, n = 813; statin use 91–180 days, n = 739; and statin use 31–90 days, n = 713) and one control cohort (cohort that used no statins, n = 4092). Study endpoint was occurrence of BPE progression (BPE diagnosis plus receiving BPE-related medications or surgery). Relative risks of BPE progression in the statin cohorts compared to the control cohort were analyzed. Results: Multivariable Cox proportional hazards regression analyses demonstrated that BPE progression risk in the cohort used statins for >365 days was significantly lower than the control cohort (adjusted hazard ratio: 0.70, 95{\%} confidence interval: 0.58 ∼ 0.85, p <.001). However, BPE progression risks of the other three statin cohorts did not significantly differ from the control cohort. Trend analysis revealed that the effects of statin treatment on decreasing BPE progression risk were significantly related to statin treatment duration (p =.001). Conclusions: Hyperlipidemia patients with long-term statin treatment (more than 365 days) are associated with a reduced risk of BPE progression.",
keywords = "benign prostate enlargement, hyperlipidemia, progression, prostate, Statin",
author = "Shih, {Hung Jen} and Tsai, {Pei Shan} and Wen, {Yu Ching} and Kao, {Ming Chang} and Fan, {Yen Chun} and Huang, {Chun Jen}",
year = "2018",
doi = "10.1080/13685538.2018.1487392",
language = "English",
journal = "Aging Male",
issn = "1368-5538",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Hyperlipidemia patients with long-term statin treatment are associated with a reduced risk of progression of benign prostatic enlargement

AU - Shih, Hung Jen

AU - Tsai, Pei Shan

AU - Wen, Yu Ching

AU - Kao, Ming Chang

AU - Fan, Yen Chun

AU - Huang, Chun Jen

PY - 2018

Y1 - 2018

N2 - Objective: To evaluate the impacts of statin treatment on the risk of benign prostatic enlargement (BPE) progression in hyperlipidemia patients. Methods: Newly diagnosed hyperlipidemia patients (n = 7961), identified from Taiwan’s National Health Insurance Research Database, were divided into four statin cohorts (statin use >365 days, n = 1604; statin use 181–365 days, n = 813; statin use 91–180 days, n = 739; and statin use 31–90 days, n = 713) and one control cohort (cohort that used no statins, n = 4092). Study endpoint was occurrence of BPE progression (BPE diagnosis plus receiving BPE-related medications or surgery). Relative risks of BPE progression in the statin cohorts compared to the control cohort were analyzed. Results: Multivariable Cox proportional hazards regression analyses demonstrated that BPE progression risk in the cohort used statins for >365 days was significantly lower than the control cohort (adjusted hazard ratio: 0.70, 95% confidence interval: 0.58 ∼ 0.85, p <.001). However, BPE progression risks of the other three statin cohorts did not significantly differ from the control cohort. Trend analysis revealed that the effects of statin treatment on decreasing BPE progression risk were significantly related to statin treatment duration (p =.001). Conclusions: Hyperlipidemia patients with long-term statin treatment (more than 365 days) are associated with a reduced risk of BPE progression.

AB - Objective: To evaluate the impacts of statin treatment on the risk of benign prostatic enlargement (BPE) progression in hyperlipidemia patients. Methods: Newly diagnosed hyperlipidemia patients (n = 7961), identified from Taiwan’s National Health Insurance Research Database, were divided into four statin cohorts (statin use >365 days, n = 1604; statin use 181–365 days, n = 813; statin use 91–180 days, n = 739; and statin use 31–90 days, n = 713) and one control cohort (cohort that used no statins, n = 4092). Study endpoint was occurrence of BPE progression (BPE diagnosis plus receiving BPE-related medications or surgery). Relative risks of BPE progression in the statin cohorts compared to the control cohort were analyzed. Results: Multivariable Cox proportional hazards regression analyses demonstrated that BPE progression risk in the cohort used statins for >365 days was significantly lower than the control cohort (adjusted hazard ratio: 0.70, 95% confidence interval: 0.58 ∼ 0.85, p <.001). However, BPE progression risks of the other three statin cohorts did not significantly differ from the control cohort. Trend analysis revealed that the effects of statin treatment on decreasing BPE progression risk were significantly related to statin treatment duration (p =.001). Conclusions: Hyperlipidemia patients with long-term statin treatment (more than 365 days) are associated with a reduced risk of BPE progression.

KW - benign prostate enlargement

KW - hyperlipidemia

KW - progression

KW - prostate

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=85050932324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050932324&partnerID=8YFLogxK

U2 - 10.1080/13685538.2018.1487392

DO - 10.1080/13685538.2018.1487392

M3 - Article

AN - SCOPUS:85050932324

JO - Aging Male

JF - Aging Male

SN - 1368-5538

ER -